**Breaking News: WHO Backs Rollout of New HIV Prevention Drug in Nigeria and Eight Other African Countries** The World Health Organisation (WHO) has given its backing to nine countries, including Nigeria, to start rolling out a new, long-acting HIV prevention medicine called Lenacapavir. This groundbreaking medicine targets people at high risk of contracting HIV in several African nations. At a virtual press conference, WHO Director-General, Dr. Tedros Ghebreyesus, revealed that the approval of Lenacapavir in 2025 marks a major breakthrough in the fight against HIV. He noted that HIV remains one of the world's most significant public health challenges, but thanks to improved treatment and increased access, annual AIDS-related deaths have dropped by about 70% over the past 20 years. The WHO chief explained that Lenacapavir is not a vaccine, but rather a long-acting antiretroviral drug that can be administered once every six months to people who are HIV-negative but at risk of infection. Clinical trials have shown that the medicine can effectively prevent HIV transmission. In Nigeria, where HIV/AIDS remains a significant public health concern, the rollout of Lenacapavir offers new hope for those at high risk of contracting the virus. According to the National Agency for the Control of AIDS (NACA), an estimated 1.9 million Nigerians are living with HIV/AIDS. The approval of Lenacapavir for HIV prevention is a significant milestone in global efforts to curb HIV transmission and accelerate progress toward ending the epidemic. With the support of the WHO, nine countries, including Nigeria, are now poised to roll out this life-saving medicine to those who need it most. As the world continues to grapple with the challenges of HIV/AIDS, the rollout of Lenacapavir offers a beacon of hope for those affected by the virus. With its long-acting nature and effectiveness in preventing HIV transmission, this medicine has the potential to transform the lives of millions of people across Africa and beyond.